Genomed Spólka Akcyjna (WSE:GEN)

Poland · Delayed Price · Currency is PLN

33.00

-0.20 (-0.60%)

At close: Sep 4, 2026

Market Cap	43.60M +26.0%
Revenue (ttm)	30.64M +21.9%
Net Income	3.51M +59.4%
EPS	2.65
Shares Out	1.32M
PE Ratio	12.44
Forward PE	n/a
Dividend	1.50 (4.46%)
Ex-Dividend Date	Jul 6, 2026

Volume	3
Open	33.20
Previous Close	33.20
Day's Range	33.00 - 33.20
52-Week Range	15.40 - 33.60
Beta	0.07
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA and RNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or seq... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2007

Employees 59

Stock Exchange Warsaw Stock Exchange

Ticker Symbol GEN

Full Company Profile

Financial Performance

In 2025, Genomed Spólka Akcyjna's revenue was 29.12 million, an increase of 26.58% compared to the previous year's 23.01 million. Earnings were 3.40 million, an increase of 207.58%.

Financial Statements